Objective To investigate the change of transforming growth factor-?1 (TGF-?1) in peripheral blood in patients with bronchial asthma and the effect of traditional Chinese medicine Ligustrazine on it. Methods We recruited 80 normal healthy people as the control group and 160 hospitalized patients, including 80 moderate cases and 80 severe cases of bronchial asthma. TGF-?1 in peripheral blood of the patients was detected by enzyme linked immunosorbent assay. The patients were treated with conventional therapy or conventional therapy added Ligustrazine; TGF-?1 in peripheral blood before and after treatment was detected and compared. Results The level of peripheral blood TGF-?1 was higher in the patient group than in the control group obviously (P

Objective To study the effect ofoxymatrine on serum matrix metalloproteinase-9 (MMP-9)and transforming growth factor-β 1 (TGF-β 1) in patients with idiopathic pulmonary fibrosis (IPF) and illuminate the mechanism and action.Methods Total 38 patients with IPF in the patient group were divided into the conventional treatment group and the oxymatrine group by random digits table method with 19 cases each.Meanwhile 38 healthy people were as the control group.Then serum MMP-9 and TGF-β1 levels were detected by enzyme-linked immunosorbent assay and compared.Results The serum MMP-9 level in the control group and the patient group was (92.30 ± 27.21),(420.66 ± 101.78) μg/L,and there was significant difference (P ＜ 0.05).The serum TGF-β 1 level in the control group and the patient group was (67.36 ± 13.03),(217.82 ±43.90) μg/L,there was significant difference (P ＜0.05).There was no significant difference in the serum MMP-9 and TGF-β1 level before treatment between the conventional treatment group and the oxymatrine group (P ＞ 0.05).There was significant difference in the serum MMP-9 level before and after treatment in the conventional treatment group [(138.91 ± 35.09) μ g/L vs.(428.21 ±102.75) μ g/L] (P ＜ 0.05).There was no significant difference in the serum MMP-9 level before and after treatment in the oxymatrine group (P ＞ 0.05).There was significant difference in the serum TGF-β 1 level before and after treatment in the conventional treatment group and the oxymatrine group [(145.42 ± 30.78)μg/Lvs.(200.34±58.96)μg/L;(102.37±26.04) μg/Lvs.(219.78±63.20) μg/L](P＜0.05).There was significant difference in the serum TGF-β1 level after treatment between the conventional treatment group and the oxymatrine group (P＜ 0.05).Conclusion Oxymatrine can degrade IPF by reducing TGF-β 1 and maintaining MMP-9 in the higher level.

Objective To explore the expressions of cardiac protein kinase C(PKC),IGF-1(insulin-like growth factor 1) and the effect of drugs in the process of left ventricular remodeling(LVRM).Methods SD rats were randomly divided into four groups: sham operation group,infracted group,Captopril group and Valsartan group.Except for sham operation group,left anterior descending coronary artery was ligated in all rats of the other three groups and the intragastric administration of solvent,100 mg?kg~(-1)?d~(-1) Captopril and 20 mg?kg~(-1)?d~(-1) Valsartan was done on day 3 after operation for 8 weeks,then LVRM was evaluated by pathologic analysis.Expression changes of cardiac AgT_(1)R,PKC,and IGF-1 were detected by immunohistochemistry and computer image analysis.IGF-1 mRNA expression was analyzed by RT-PCR.Results LVW,LVWI and the expressions of AgT_(1)R,PKC,IGF-1 mRNA and proteins were significantly enhanced(P

Aim To research the effects of HSP70 in-hibitor ( PFTμ) on the expressions of iNOS induced by IFN-γ in RAW 264. 7 cells. Methods The NO con-centration was measured by Griess Kit. The expression of interest protein was measured by Western blot and iNOS mRNA was measured by RT-PCR. Mouse cardi-ac ischemia-reperfusion ( I/R ) model was established to set up the inflammatory response. These were divid-ed into control and treated groups. The infarct size was monitored on myocardial I/R mice. Results We found that PFTμsignificantly blocked the production of NO and the expression of iNOS protein and mRNA in RAW 264. 7 cells. The mechanism may be part of the inhibition of nuclear IRF-1 protein expression. We also found that PFTμ reduced the infarct size in myocardial I/R mice ( P <0. 05 ) . Conclusion These results suggest that PFTμ down-regulates the IFN-γ-induced iNOS transcription through decreasing translocated IRF-1 protein.

Objective To study the cause,clinical characteristics and treatment of HFmrEF,HFrEF and HFpEF patients.Methods Three hundred and eighty-five heart failure (HF) patients aged ≥60 years admitted to our hospital from January 2016 to March 2017 were divided into HFrEF group (n=96),HFmrEF group (n=34) and HFpEF group (n=255) according to their ejection fraction.Their demographic data,HF cause,clinical characteristics,cardiac ultrasonographic data,laboratory testing data and therapies were recorded.Their clinical characteristics were compared.Results The number of males was greater and the cardiac function grade Ⅳ was higher in HFmrEF group than in HFrEF and HFpEF groups.The incidence of hypertension was the highest followed by that of valvular disease.The number of HFmrEF patients who used intravenous nitrates,spironolactone and milrinone was greater than that of HFpEF and HFrEF patients who used intravenous nitrates,spironolactone and milrinone.The serum creatinine level was higher in HFmrEF patients than in HFpEF and HFrEF patients at the time when they were discharged.Conclusion Hypertension and valvular disease are the mian risk factors for HFmrEF.The number of males is greater and the cardiac function grade Ⅳ is higher in HFmrEF patients than in HFrEF and HFpEF patients.The serum creatinine level is higher and the outcome is better in HFmrEF patients than in HFrEF and HFpEF patients at the time when they are discharged.

Aim To investigate the effects of CYP2C19 polymorphism on the pharmacokinetics and comparative bioavailability of omeprazole in Chinese population.Methods Eighteen healthy male volunteers were selected,of whom 6 were CYP2C19 wild type(w/w),6 were CYP2C19 heterozygous variant(w/m) and the rest were CYP2C19 homozygous variant(m/m).A randomized two-period crossover study was performed.Subjects were assigned to receive test or reference omeprazole as a single oral dose of 40 mg randomly.After a washout period of one week,subjects received the alternative omeprazole formulation.Multiple blood samples of 3 ml were obtained over 12 h after dosing and plasma concentrations of omeprazole were measured by LC/MS method.The modeling of individual pharmacokinetics and the pharmacokinetic parameters of omeprazole were estimated by 3P97.Results The AUC and Cmax of reference omeprazole formulation in w/w,w/m,m/m groups were 1178.44±340.24,2328.10±1011.83,5062.02±1097.29 μg·h·L~(-1) and 602.87±118.25,926.43±134.48,1406.29±233.58 μg·L~(-1),respectively,with significant differences among the three groups(P<0.05).Significant differences were also observed in other pharmacokinetic parameters such as k_e、CL/F、t_(1/2) and Vd/F among the three groups(P<0.05).With regard to test omeprazole formulation,the AUC and C_(max) in w/w,w/m,m/m groups were 1224.82±531.67,2723.34±519.29,5692.49±1575.35 μg·h·L~(-1) and 618.74±231.43,910.67±125.99,1303.31±152.01 μg·L~(-1),respectively,which,as well as k_e,CL/F,t_(1/2) and Vd/F were significant different among the three groups(P<0.05).No significant differences were observed in comparative bioavailability among groups with the values of 94.29%±14.06%,93.08%±11.22%,91.84%±13.03% in w/w,w/m,m/m groups respectively(P>0.05).Conclusions Different CYP2C19 genotypes,leading to functional heterogeneity of CYP2C19,may affect pharmacokinetic profile of omeprazole.Therefore,genotyping CYP2C19 gene before omeprazole therapy will be of great benefit for optimizing individual therapy regimen.There is no significant difference of omeprazole comparative bioavailability with regard to CYP2C19 genetic polymorphism.

Objective To investigate the role of NF-κB activation in the inflammatory mechanism of chronic obstructive pulmonary disease (COPD).Methods Monocyte were collected from patients with COPD and were cultured,and stimulated with lipopolysaccharide (LPS) ; NF-κB p65 activation was measured by immunohistochemistry; SOD ,MDA and IL-8 and lung function were determined synchronously.Results The NF-κB p65 was induced by LPS in monocyte in all subjects, but it was most markedly done in COPD patients with exacerbateions; There was positive correlation between the NF-κB p65 activation of monocytes and levels of IL-8 and MDA in circulation, but it was negative correlation to SOD.Conclusion NF-κB plays a vital role in regulating product of IL-8 in monocyte in COPD.

Objective To explore the effects of SLC concentration gradient on suppression of tumor immune escape. Methods According to different SLC concentration, there were six groups. The HLA-Ⅰexpression and apoptosis of MCF-7 were detected with FCM,and intracellular BCL-2 expression was analyzed by western blot. The production of TGF-? was detected with ELISA. Results In a certain range of concentration gradient, following SLC increase, HLA-Ⅰexpression level on MCF-7 was improved, and apoptosis was induced but BCL-2 expression was enhanced. Moreover, the secretion of TGF-? was suppressed. Conclusion SLC inhibites tumor immune escape.

Objective To determine the diagnostic value of ractional exhaled nitric oxide (FeNO) in eosinophils (EOS) bronchial asthma and its significance in appraising of therapeutic reaction of inhaled corticosteroids (ICS) for EOS bronchial asthma.Methods A total of sixty-two patients with bronchial asthma in the First Mfiliated Hospital of Xinxiang Medical University from April 2015 to February 2016 were selected as asthma group;at the same time,sixty-two healthy people were recruited as control group.The patients in asthma group were divided into EOS asthma group(n =31) and non EOS asthma group (n =31) according to the induced sputum cell count;the patients in EOS asthma group were divided into mild (n =7),moderate (n =13) and sever asthma group (n =1 1) according to the severity of the disease.The patients in asthma group were given conventional therapy(doxofylline 0.2 g intravenous infusion,two times per day;oral cetirizine 10 mg,one time per night;oral montelukast 10 mg,one time per night;budesonide 2 mg and compound ipratropium bromide solution 2.5 mL by aerosol rebreathing method,two times per day) for seven days.The pulmonary function,asthma control test(ACT) score,FeNO level and the ratio of EOS of patients were detected before and after treatment;the FeNO levels of person in the control group were tested.The FeNO levels of subjects were compared in each group;the correlation between FeNO level and EOS ratio was analysed in asthmatic group;the controlling rates of patients in asthmatic group were compared.Results Before treatment,the FeNO level in control group and asthma group was (9.57 ± 6.61),(30.23 ± 8.9 1) ppb respectively;the FeNO level in control group was significantly lower than that in asthma group (t =7.414,P ＜ 0.05).Before treatment,the FeNO level of patients in EOS asthma group and non EOS asthma group was (59.62 ± 29.04),(18.20 ± 11.33) ppb respectively;the FeNO level in non EOS asthma group was lower than that in EOS asthma group (t =6.568,P ＜ 0.05).In asthma group,the level of FeNO was positively correlated with EOS ratio(r =0.823,P ＜ 0.05).There was no statistic difference in FeNO level of patients in non EOS asthma group before and after treatment(t =2.013,P ＞ 0.05).The FeNO levels of patients in EOS asthma group after treatment were significantly lower than those before treatment (t =7.740,P ＜ 0.05);the FeNO levels of patients in mild,moderate and sever asthma group after treatment were significantly lower than those before treatment(t =3.535,8.171,7.161;P ＜0.05).The control rate of patients in EOS asthma group(67.7％,21/31) was significantly higher than that in the non EOS asthma group(22.6％,7/31) (x2 =12.765,P ＜0.05).The control rate of patients in mild,moderate and sever asthma group was 28.6％ (2/7),76.9 ％ (10/13) and 81.8 ％ (9/11) respectively;the control rate of patients in mild asthma group was significantly lower than that in moderate and sever asthma group (x2 =6.418,7.103;P ＜ 0.05);there was no statistic difference in control rate of patients between moderate asthma group and sever asthma group(x2 =7.103,P ＞ 0.05).Conclusion FeNO level can reflect the degree of airway inflammation,and can be used for the diagnosis of EOS phenotype asthma,and also has certain clinical value in evaluating the therapeutic reaction of ICS for treatment of EOS asthma.

OBJECTIVE To prevent occurrence of infection in clinical laboratory. METHODS The biosafety system was continuously improved and complet step by step and amplifed rules and regulation,done well protection of person,making the operating process of laboratory more norma,enforcing the air and environment,sterilizeing the equipment,detecting implement,disinfecting the used material and medical garbage and inspecting. RESULTS The hospital infection in laboratory was effectly controlled,the staff′s safety and health were addressd when they worked in an infected area of laboratory. CONCLUSIONS Amplifying the rules and regulation,and insisting the principle of work without slacking could effecttively prevent the occurring of hospital infection in clinical laboratory.